Table 3.

Relationship between use of statins and breast cancer risk by solubility and for the most commonly used statin medications

Controls (n = 877)Ductal cases (n = 891)Lobular cases (n = 1,036)
N (%)N (%)OR (95% CI)N (%)OR (95% CI)
Never use674 (76.9)664 (74.8)1.00 (reference)782 (75.6)1.00 (reference)
Hydrophilic statins
Current use13 (1.5)18 (2.0)1.56 (0.75–3.24)21 (2.0)1.65 (0.81–3.38)
Lipophilic statins
Current use157 (17.9)166 (18.7)1.13 (0.88–1.45)196 (18.9)1.21 (0.95–1.54)
 6 months–<5 years84 (9.6)76 (8.6)0.95 (0.68–1.33)104 (10.1)1.17 (0.86–1.61)
 5 yrs–<10 yrs44 (5)45 (5.1)1.09 (0.70–1.69)44 (4.3)0.96 (0.62–1.50)
 ≥10 years28 (3.2)43 (4.8)1.74 (1.05–2.86)45 (4.4)1.68 (1.02–2.76)
PtrendP = 0.119P = 0.094
Atorvastatin
Current use77 (8.8)93 (10.5)1.34 (0.96–1.85)98 (9.5)1.25 (0.91–1.74)
 6 months–<5 years37 (4.2)47 (5.3)1.39 (0.88–2.17)56 (5.4)1.46 (0.94–2.25)
 5 yrs–<10 yrs28 (3.2)26 (2.9)1.01 (0.58–1.77)24 (2.3)0.85 (0.48–1.51)
 ≥10 years12 (1.4)20 (2.3)1.97 (0.94–4.11)18 (1.7)1.55 (0.73–3.30)
PtrendP = 0.048P = 0.254
Simvastatin
Current use50 (5.7)49 (5.5)0.97 (0.64–1.48)57 (5.5)1.05 (0.70–1.57)
 6 months–<5 years30 (3.4)29 (3.3)0.93 (0.54–1.58)35 (3.4)1.03 (0.62–1.72)
 5 yrs–<10 yrs14 (1.6)12 (1.4)0.94 (0.42–2.07)13 (1.3)0.90 (0.41–1.96)
 ≥10 years6 (0.7)8 (0.9)1.30 (0.44–3.85)9 (0.9)1.49 (0.52–4.28)
PtrendP = 0.729P = 0.681

NOTE: OR adjusted for reference year, reference age, county of residence, and hormone therapy use. Bold values signify statistically significant estimates (P value <0.05).